Leukosight Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 5


  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 3

Leukosight General Information


Provider of anti-inflammatory therapeutics. The company offers therapeutics that can be used to treat auto-immune and inflammatory diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Corporate Office
  • 1107 Microbiology Building
  • 231 B Campus Drive
  • College Park, MD 20742
  • United States
+1 (301) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Leukosight Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private Completed Generating Revenue
4. Grant 03-May-2012 00000 Completed Startup
3. Grant 01-Jan-2012 00000 Completed Startup
2. Early Stage VC Completed Startup
1. Grant 01-May-2009 $150K Completed Startup
To view Leukosight’s complete valuation and funding history, request access »

Leukosight Patents

Leukosight Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20120283417-A1 Polypeptides comprising fc fragments of immunoglobulin g (igg) and methods of using the same Inactive 04-Dec-2008 0000000000 0
US-20140294817-A1 Polypeptides comprising fc fragments of immunoglobulin g (igg) and methods of using the same Inactive 04-Dec-2008 0000000000
US-20100143353-A1 Polypeptides comprising fc fragments of immunoglobulin g (lgg) and methods of using the same Inactive 04-Dec-2008 C07K16/244 00

Leukosight Executive Team (1)

Name Title Board Seat Contact Info
David Mosser Ph.D Founder, President & Chief Executive Officer
To view Leukosight’s complete executive team members history, request access »

Leukosight Board Members (2)

Name Representing Role Since
Steven Burke MD Self Board Member 000 0000
You’re viewing 1 of 2 board members. Get the full list »

Leukosight Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Leukosight Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Maryland Biotechnology Center Government 000 0000 000000 0
National Institute for Allergy and Infectious Disease Government 000 0000 000000 0
TEDCO Venture Capital Minority 000 0000 000000 0
To view Leukosight’s complete investors history, request access »

Leukosight FAQs

  • When was Leukosight founded?

    Leukosight was founded in 2006.

  • Who is the founder of Leukosight?

    David Mosser Ph.D is the founder of Leukosight.

  • Who is the CEO of Leukosight?

    David Mosser Ph.D is the CEO of Leukosight.

  • Where is Leukosight headquartered?

    Leukosight is headquartered in College Park, MD.

  • What is the size of Leukosight?

    Leukosight has 5 total employees.

  • What industry is Leukosight in?

    Leukosight’s primary industry is Drug Discovery.

  • Is Leukosight a private or public company?

    Leukosight is a Private company.

  • What is Leukosight’s current revenue?

    The current revenue for Leukosight is 000000.

  • Who are Leukosight’s investors?

    Maryland Biotechnology Center, National Institute for Allergy and Infectious Disease, and TEDCO have invested in Leukosight.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »